Compass Group PLC shares fell 7.7% to 2,050p on Thursday despite posting a trading update for what it called a strong start to the year and reaffirming its full-year guidance. The FTSE 100 catering group reporting 7.3% organic revenue growth for the first quarter, which was down from the 8.7% growth seen in the past full year.
The recent pullback in Compass Group PLC (LSE:CPG) shares is unjustified, according to UBS, which argues that the market's concerns around the potential impact of AI on employment and demand for workplace catering are overcooked. In a note to clients, the Swiss bank noted that some investors view the FTSE 100 group as an "AI loser", hit by second-order effects as job displacement in the wider economy leads to top-line pressure.
Compass Therapeutics remains a 'Buy,' but valuation above $1B stretches risk/reward as it awaits pivotal clinical catalysts. Tovecimig's early data in biliary tract and refractory colorectal cancers show promise, with key COMPANION-002 updates expected late Q1 2026. CMPX's cash runway extends into 2028, supporting continued clinical progress and mitigating near-term financing risk.
Compass (COMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Compass Pathways plc experienced an >80% rally since my last 'Hold' rating. CMPS has benefited from positive phase 3 trial results and positive political developments since my last article. Recent approval of JNJ's Spravato as a standalone product in treatment of TRD offers significant piggybacking opportunity for Compass.
Compass (COMP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Compass Diversified faces severe financial distress following the Lugano fraud, with breached debt covenants and a "Going Concern" warning. CODI's restated Q1 results reveal a dramatic reduction in revenues and profitability, with EBITDA guidance slashed from $570m-$610m to $330m-$360m. Lugano's Chapter 11 filing and deconsolidation will further reduce inventories by 40% and Lugano revenues by 85%, compounding CODI's challenges.
Here is how Compass, Inc. (COMP) and Amtech Systems (ASYS) have performed compared to their sector so far this year.
Mike Simonsen, Compass Chief Economist, joins 'Fast Money' to talk whats ahead for the housing market in 2026.
Butterfly Network, Inc. (BFLY) is rated 'Hold' as recent upside from the Midjourney licensing deal appears fully priced in. BFLY's high valuation is at odds with ongoing unprofitability, significant inventory write-downs, and slower revenue growth versus peers. Core upside hinges on successful adoption of Compass AI and POCUS stack to drive recurring, higher-margin revenue.
Compass Minerals International (CMP) delivered a strong Q4 FY25, with revenue and adjusted EPS exceeding expectations and promising FY26 guidance. CMP remains attractively valued, trading at significant discounts to peers on cash flow and EBITDA multiples, despite higher leverage. Salt segment volume surged due to normalized winter weather, while Plant Nutrition saw higher pricing offsetting lower volumes, driving profitability improvements.
Yesterday we were watching whether Compass Minerals could stabilize its bottom line after a brutal fiscal 2024.